Category
Health Policy
Articles in this category

9/2/2026
Korea AI Basic Healthcare Strategy Targets Global Biohealth Leadership
South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess
Read Article →
9/2/2026
EMA Scientific Advice Hits Record Volumes as Agency Plans Agile Pilot
EMA scientific advice volumes hit a record in the first half of 2026. The agency is planning pre-payment at submission, an agile advice pilot for 2027, and a regulatory sandbox workshop in September. #SyenzaNews #EMA #MarketAccess #DrugDevelopment
Read Article →
9/1/2026
Portugal private health insurance premiums average €466 a year, up 9.1%
Portuguese private health insurers cleared €1 billion in six months as premiums climbed 9.1% to €466 a year. #SyenzaNews #HealthInsurance #Portugal #MarketAccess
Read Article →
9/1/2026
US Expands MFN Drug Pricing to 26 Manufacturers
The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma
Read Article →
8/31/2026
Linking Drug and Diagnostic Policy Pathways to Reach Patients Most Likely to Benefit
Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess
Read Article →
8/31/2026
AI Models Near Perfect Scores on German Medical Licensing Exams
A new benchmark in npj Digital Medicine finds frontier AI models at near-perfect accuracy on German medical licensing exams, yet image questions still cut their scores far more than for students. #SyenzaNews #AIinHealthcare #DigitalHealth
Read Article →
8/28/2026
Fifth Circuit Upholds Medicare Drug Price Negotiation Program
The Fifth Circuit affirmed the constitutionality of the Medicare drug price negotiation program, rejecting claims from NICA, the Global Colon Cancer Association, and PhRMA. #SyenzaNews #DrugPricing #MarketAccess #Pharma
Read Article →
8/28/2026
Investing in Future Generations Through the Economics of Health for All
Finland, UNRISD and the WHO asked what the Economics of Health for All strategy means for the next generation, from intergenerational fairness and participatory foresight to dignified access to care. #SyenzaNews #HealthEconomics #WellbeingEconomy
Read Article →
8/28/2026
Drug Reimbursement in France Keeps Rising. So Why Do Patients Feel Shortchanged?
France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy
Read Article →
8/27/2026
Specialist Payment Models: Triple the Cardiac Testing, No Difference in Outcomes
In Alberta, patients of fee-for-service heart specialists receive roughly three times the cardiac testing, with no measurable difference in outcomes. #HealthEconomics #PhysicianPayment #SyenzaNews
Read Article →
8/26/2026
Health Department: Local Pharma’s Woes Are Regulatory, Not a Failure of Procurement
South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.
Read Article →
8/24/2026
Trodelvy Metastatic TNBC Approval Expands First-Line Options
The European Commission has approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making Trodelvy the first ADC-based backbone across PD-L1 status.
Read Article →


